At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SONN Sonnet BioTherapeutics Holdings, Inc.
Pre-Market Trading 12-23 08:03:29 EST
1.56
-0.03
-1.89%
盘前1.62
+0.06+3.69%
08:01 EST
High1.70
Low1.55
Vol233.24K
Open1.60
D1 Closing1.59
Amplitude9.43%
Mkt Cap4.69M
Tradable Cap4.62M
Total Shares3.01M
T/O379.99K
T/O Rate7.87%
Tradable Shares2.96M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.